Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $6.2050 (-3.5%) ($6.2050 - $6.2050) on Fri. Nov. 26, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.84% (three month average) | RSI | 64 | Latest Price | $6.2050(-3.5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.3% a day on average for past five trading days. | Weekly Trend | AUTL declines -2.5% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(62%) IBUY(57%) ARKG(54%) ARKK(54%) IWO(54%) | Factors Impacting AUTL price | AUTL will decline at least -2.42% in a week (0% probabilities). VIXM(-41%) VXX(-33%) TLT(-29%) SHY(-23%) BNDX(-18%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.42% (StdDev 4.84%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
Resistance Level | $6.32 | 5 Day Moving Average | $6.26(-0.88%) | 10 Day Moving Average | $6.48(-4.24%) | 20 Day Moving Average | $6.32(-1.82%) | To recent high | -15.8% | To recent low | 12% | Market Cap | $324m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |